TCDA stock information

Sector:

Healthcare

Description:

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Tricida, Inc. website

Current Price

$0.11

RSI

14.62

Market Capitalization:

468.7M

Beta:

1.091

Volume:

31,125,310

Analyst Target Price:

$ 15.67

Economiic Fair Price:

Earnings DateNovember 14, 2022

Report DateNovember 14, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash17.7M

Debt208M

EPS-3.608

Profit MarginN/A

Revenue Per Share TTM0

Return On Equity TTM-2.231

2021 Free Cash Flow

$ -140.2M

39.79 %

2020 Free Cash Flow

$ -232.8M

-77.69 %

2019 Free Cash Flow

$ -131M

-36.88 %

2018 Free Cash Flow

$ -95.7M

-131.16 %

2017 Free Cash Flow

$ -41.4M

-77.22 %

2016 Free Cash Flow

$ -23.4M

Tricida, Inc.(TCDA)